Navigation Links
Third Pivotal Phase 3 Study for NicOx' Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
Date:11/24/2008

SOPHIA ANTIPOLIS, France, November 24 /PRNewswire-FirstCall/ -- NicOx S.A. (NYSE Euronext Paris: COX) today announced that the third pivotal phase 3 study for naproxcinod in patients with OA of the hip showed a highly statistically significant result (p<0.001) on all three co-primary efficacy endpoints of the trial. Naproxcinod 750 mg bid showed the same gastrointestinal (GI) adverse event rate and a similar blood pressure profile to placebo. Naproxcinod is the most advanced compound in a novel class of anti-inflammatory agents known as Cyclooxygenase-Inhibiting Nitric Oxide Donators (CINODs).

Following the positive results from the 301 and 302 studies in patients with OA of the knee, 303 represents the third phase 3 study for naproxcinod to achieve p<0.001 on all three co-primary efficacy endpoints. The 303 study is also the final pivotal trial that NicOx plans to include in the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) in mid-2009.

"This study has demonstrated clear-cut efficacy for naproxcinod 750 mg bid in hip OA, in addition to providing reassuring blood pressure and safety data," said Thomas J. Schnitzer, MD, PhD, Professor of Medicine at Northwestern University Feinberg School of Medicine, who advised NicOx on the design and analysis of the trial. "Meeting the primary endpoints of this study is a significant achievement, considering the difficultly in controlling the symptoms of hip OA patients. Few studies with other anti-inflammatory agents have focused only on people with hip OA, in part because of the increased difficulty in demonstrating efficacy in this population compared to knee OA. Additionally, the fact that the blood pressure data for naproxcinod and placebo were similar at all time points is also encouraging, as there is a definite need for new anti-inflammatory agents that do not increase blood pressure."

Result
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

13611

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Over $10 Million of CSL Behrings Privigen Was Sold in the U.S. During the Third Quarter of 2008
2. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
3. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
4. CuraGen to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and CR011-vcMMAE Phase II Trial Results on November 3, 2008
5. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
6. Physicians Estimate That if Approved, Ceftobiprole Will Steal Nearly a Third of Zyvoxs Patient Share in the Treatment of Nosocomial Pneumonia
7. NewCardio Announces Positive Results From Third Clinical Validation Study
8. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
9. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
10. NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit
11. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Inivata, a Cambridge, England ... presence at the 2015 American Association for Cancer Research (AACR) ... Nitzan Rosenfeld and a poster presentation. Michael Stocum ... - 22 nd . The presentation, entitled ... forms part of a session on Recent Advances ...
(Date:4/17/2015)... Research and Markets ( http://www.researchandmarkets.com/research/dl9gbg/admetoxicology ) ... - Global Strategic Business Report" report to their ... for ADME-Toxicology Testing in US$ Million by the following ... The report provides separate comprehensive analytics for ... Japan , Europe , ...
(Date:4/17/2015)... Research and Markets ( http://www.researchandmarkets.com/research/vrd3bd/mammography ) ... - Global Strategic Business Report" report to their ... for Mammography Equipment in US$ Thousands by the following ... The report provides separate comprehensive analytics for the US, ... , Europe , Asia-Pacific ...
Breaking Medicine Technology:Inivata Co-founder Nitzan Rosenfeld to Present at AACR Annual Meeting 2ADME-Toxicology Testing (In-Vivo, & In-Vitro) Market - Global Strategic Business Report 2015: Pharma Industry Renews Focus on Cost Optimization 2Mammography Equipment (Analog & Digital) Market 2015-2020 - Global Strategic Business Report: Breast Imaging Screening Programs Push Sales 2
... THE WOODLANDS, Texas, Feb. 16, 2012   Lexicon Pharmaceuticals, ... company focused on discovering breakthrough treatments for human disease, ... financial results on Wednesday, February 22, 2012 before the ... call and webcast to discuss clinical development progress and ...
... 16, 2012  2WIN! Global,s Bob Riefstahl will deliver the ... Diagnostic Sales Training and Development Conference in Phoenix next ... hearing it again and again from your sales and ... 2WIN! Global CEO and Founder, Bob Riefstahl. "For over ...
Cached Medicine Technology:Lexicon to Report Fourth Quarter and Year End 2011 Financial Results on February 22, 2012 22WIN! ® Global Keynotes at Upcoming Medical Device Conference: 2
(Date:4/17/2015)... (PRWEB) April 17, 2015 Scientists ... a multicenter team of U.S. and Venezuelan researchers, ... yet in humans among an isolated tribe of ... Venezuela. Bacterial diversity in the Yanomami, previously unexposed ... be nearly double that of people living in ...
(Date:4/17/2015)... Calvary Hospital recently announced Timothy P. Barr will be ... May 11. The Fund directs all fundraising efforts in support ... J. Spinelli, who retired several months ago. , “We are ... the important work that the Fund does every year,” said ... expand and bring our signature care to people who need ...
(Date:4/17/2015)... NJ (PRWEB) April 17, 2015 ... in the posterior pituitary and thought to help mothers ... between couples. To further substantiate this, new studies performed, ... the journal, Nature, and reported by Medical News Today ... a powerful influence over maternal social behavior. The study ...
(Date:4/17/2015)... New York, NY (PRWEB) April 17, 2015 ... is formulated to polish and perfect facial ... Ecuadorian Ivory Palm seeds and blend of energizing ... dulling dead skin cells that cause breakouts and ... , Star Ingredients: , Ecuadorian Ivory Palm Seeds, ...
(Date:4/17/2015)... 17, 2015 According to the ... 50 million Americans suffer from all types of allergies, ... eye allergies. Thanks to comprehensive allergy testing that’s being ... ), there’s now a way to get recommended treatment ... “Allergy triggers, or allergens, can vary by region of ...
Breaking Medicine News(10 mins):Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3Health News:Timothy P. Barr Appointed Executive Vice President of Calvary Fund 2Health News:Timothy P. Barr Appointed Executive Vice President of Calvary Fund 3Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 2Health News:Oxytocin Now Found to Help Diet Doc Patients Whose Weight Has Gotten out of Control Due to Emotional Eating Disorders 3Health News:Mario Badescu Skin Care Launches Botanical Exfoliating Scrub 2Health News:CareMed Urgent & Primary Care Now Offering Comprehensive Allergy Testing 2Health News:CareMed Urgent & Primary Care Now Offering Comprehensive Allergy Testing 3
... New England Journal of Medicine suggested that moderate drinking ... individuals. The study was conducted over a 12-year period ... osteopathic physicians and podiatrists, aged 40 to 75 years. ... frequency of drinking. ,The study showed that it ...
... A study which appeared in the clinical journal ... associated with a five-year risk of ocular hypertension, ... prevalence// of glaucoma, in Caucasians. The study was ... to 84, who received baseline assessments of refractive ...
... Cancer and Leukemia Group B (CALGB) and presented at ... the effectiveness of reducing the interval between successive doses ... rates in breast cancer// women. This study was conducted ... in the 1980s that suggested the value of increased ...
... cancer has been associated to many risk factors like ... consumption. Several earlier studies have linked alcohol to breast ... because smoking often accompanies drinking, researchers have not been ... ,Now, researchers from Cancer Research, UK, who included dozens ...
... American Medical Association published a recent comparative study done ... results from a telephone survey of people living in ... who were asked to name up to three stroke ... a similar survey conducted in 1995 to study the ...
... a recent study have found that people who take ... higher risk of developing gastrointestinal bleeding. The study which ... anti-depressant// users, who were compared for hospitalizations due to ... ,Researchers found people on selective serotonin reuptake inhibitors, or ...
Cached Medicine News:Health News:Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy" 2
The Unistik 3 family of single use safety lancets has 4 models for use across all clinical environments....
The Stat-Let lines of disposable lancets are all designed with the goals of providing a safe and easy to achieve capillary blood sampling. All of our lancets can be used by most current models of lan...
The BD Ultra-Fine 33 Lancets are the thinnest lancets available, which means that you'll experience less pain when taking a blood sample....
... flow and minimize pain when performing ... BD Microtainer Quikheel Lancet. The simple ... providing a precise and consistent incision, ... its casing, helping to protect you ...
Medicine Products: